Liminatus Pharma, Inc. (LIMN:NASDAQ) closed at $3.04 on October 16, 2026, down 5.30% on the day. The stock trades 97.9% below its 52-week high of $141.50 and 1.0% above its 52-week low of $3.01. Liminatus Pharma, Inc. is part of the Health Care sector.
| 5D | 1M | 3M | 6M |
|---|---|---|---|
| -11.88% | -10.32% | -46.67% | -71.72% |
In 251 trading sessions since October 16, 2025, LIMN closed higher on 97 days (39%). Its best day was February 3, 2026 (+87.39%) and its worst was February 11, 2026 (-52.62%). The stock moved 10% or more in a single session 37 times. It opened at least 5% above the previous day's high 4 times.
Liminatus Pharma, Inc. is pre-clinical stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company's candidate IBA101, is a humanized anti CD47 monoclonal antibody. The next generation CD47 checkpoint inhibitor's initial indication is expected to be patients with advanced solid cancers including non-small cell lung cancer. The Company's vision is to develop a broad array of transformative therapies for cancer patients as a leading global biopharmaceutical company.
Find more stocks like LIMN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.